BACKGROUND: A clinically isolated syndrome (CIS) may be the initial presentation of multiple sclerosis (MS). However, some CIS never develop MS. The identification of patients at risk of MS conversion is crucial as early treatment may improve their outcome. Free kappa chains (FKC) are increased in cerebrospinal fluid (CSF) of MS patients. We studied the accuracy of CSF FKC level measurement, using a new nephelometric test, to predict conversion of CIS patients to MS. METHODS: We calculated linearity and inter-assay variability of the FKC test for CSF values and quantified this protein in CSF from 25 patients with non-inflammatory neurological diseases (NIND) and 78 consecutive CIS patients. We assessed whether high CSF FKC levels associate with CIS conversion to clinically definite MS, defined as the onset of new relapses during follow-up. RESULTS: Between 0.1 and 5mg/l the FKC test showed linearity of 0.98 and inter-assay correlation coefficient of =0.99. A cut-off value of 0.53 mg/l (mean+2SD of NIND group CSF FKC values) was calculated. CIS patients with CSF FKC above this value showed earlier conversion to MS in univariate and multivariate Cox analysis (HR=6.41; 95% CI=1.88-21.78, p=0.003). CONCLUSION: High CSF FKC levels accurately predict CIS patient conversion to MS.
BACKGROUND: A clinically isolated syndrome (CIS) may be the initial presentation of multiple sclerosis (MS). However, some CIS never develop MS. The identification of patients at risk of MS conversion is crucial as early treatment may improve their outcome. Free kappa chains (FKC) are increased in cerebrospinal fluid (CSF) of MS patients. We studied the accuracy of CSF FKC level measurement, using a new nephelometric test, to predict conversion of CIS patients to MS. METHODS: We calculated linearity and inter-assay variability of the FKC test for CSF values and quantified this protein in CSF from 25 patients with non-inflammatory neurological diseases (NIND) and 78 consecutive CIS patients. We assessed whether high CSF FKC levels associate with CIS conversion to clinically definite MS, defined as the onset of new relapses during follow-up. RESULTS: Between 0.1 and 5mg/l the FKC test showed linearity of 0.98 and inter-assay correlation coefficient of =0.99. A cut-off value of 0.53 mg/l (mean+2SD of NIND group CSF FKC values) was calculated. CIS patients with CSF FKC above this value showed earlier conversion to MS in univariate and multivariate Cox analysis (HR=6.41; 95% CI=1.88-21.78, p=0.003). CONCLUSION: High CSF FKC levels accurately predict CIS patient conversion to MS.
Authors: David Zeman; Pavlína Kušnierová; Zdeněk Švagera; František Všianský; Monika Byrtusová; Pavel Hradílek; Barbora Kurková; Olga Zapletalová; Vladimír Bartoš Journal: PLoS One Date: 2016-11-15 Impact factor: 3.240
Authors: P Menéndez-Valladares; M I García-Sánchez; P Cuadri Benítez; M Lucas; M Adorna Martínez; V Carranco Galán; J L García De Veas Silva; C Bermudo Guitarte; G Izquierdo Ayuso Journal: Mult Scler J Exp Transl Clin Date: 2015-12-16
Authors: Makbule Senel; Fatemeh Mojib-Yezdani; Ulrike Braisch; Franziska Bachhuber; Jan Lewerenz; Albert C Ludolph; Markus Otto; Hayrettin Tumani Journal: Front Immunol Date: 2019-03-29 Impact factor: 7.561
Authors: Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Kurt-Wolfram Sühs; Hayrettin Tumani; Marie Süße; Thomas Skripuletz Journal: Cells Date: 2021-11-06 Impact factor: 6.600
Authors: Jéssica Castillo-Villalba; Sara Gil-Perotín; Raquel Gasque-Rubio; Laura Cubas-Nuñez; Sara Carratalà-Boscà; Carmen Alcalá; Carlos Quintanilla-Bordás; Francisco Pérez-Miralles; Cristina Ferrer; Antonio Cañada Martínez; Jordi Tortosa; Luís Solís-Tarazona; Luisa Campos; Alberto Leivas; Begoña Laíz Marro; Bonaventura Casanova Journal: Front Immunol Date: 2022-03-07 Impact factor: 7.561
Authors: Klaus Berek; Gabriel Bsteh; Michael Auer; Franziska Di Pauli; Astrid Grams; Dejan Milosavljevic; Paulina Poskaite; Christine Schnabl; Sebastian Wurth; Anne Zinganell; Thomas Berger; Janette Walde; Florian Deisenhammer; Harald Hegen Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-05-28